文献速递免疫规划慢病防控与筛查卫生政策与健康促进

2017-2021年美国成人两剂重组带状疱疹疫苗依从性与完成率的真实世界证据及相关因素

Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
PubMed 文献 · Vaccine · 2022-03-12

这项回顾性观察研究利用大型行政索赔数据库,分析了2017年4月20日至2021年3月31日期间接种重组带状疱疹疫苗(RZV)的≥50岁美国成人。在726,352名成人中,依从率为71.8%;在208,311名有24个月随访的成人中,完成率6个月后为72.3%,24个月后为86.2%。低依从/完成与较年轻年龄、黑人/西班牙裔、较低收入、较低教育程度及拥有商业保险而非Medicare保险相关。

要点

  • 在726,352名接种RZV的≥50岁成人中,依从率为71.8%。
  • 在有24个月随访的208,311名成人中,完成率6个月后为72.3%,24个月后为86.2%。
  • 药房索赔识别者的依从率(74.0%)高于医疗索赔识别者(48.0%)。

核心结论

  • RZV的依从率和完成率不理想,尤其是在50-64岁成人、种族/族裔少数群体、社会经济地位较低者及无Medicare保险者中。
  • 需要更多研究和公共卫生努力来理解和解决RZV接种、依从和完成的潜在障碍。

研究设计与样本

  • 回顾性观察研究,使用大型、地理代表性行政索赔数据库。
  • 纳入2017年4月20日至2021年3月31日期间接种RZV的≥50岁美国成人,要求索引日期(首次观察到的疫苗剂量)前后6个月连续参加医疗福利计划。
  • 依从性定义为按标签建议在2-6个月内接种第二剂;完成率(接种所有剂量)在6、12、18和24个月时评估。
  • 共纳入726,352名成人;其中208,311名成人有24个月随访。

主要发现

  • 726,352名成人的依从率为71.8%。
  • 208,311名有24个月随访的成人中,完成率6个月后为72.3%,24个月后为86.2%。
  • 逻辑回归显示低依从/完成与较年轻年龄、黑人/西班牙裔种族/族裔、较低收入、较低教育程度及拥有商业保险而非Medicare保险相关。
  • 药房索赔识别者的依从率(74.0%)高于医疗索赔识别者(48.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Poor compliance with adult vaccination recommendations contributes to substantial disease burden. Evidence on adherence, completion, and completion timeliness for the 2-dose recombinant herpes zoster vaccine (RZV) and factors associated with these outcomes is limited and not readily generalizable for the entire U.S. METHODS: This retrospective, observational study examined adherence, completion, and the impact of sociodemographic, clinical and geographical factors among U.S. adults ≥ 50 years receiving RZV (4/20/2017 to 3/31/2021), using a large, geographically representative administrative claims database. Continuous enrollment in a medical benefit plan for six months prior to and following the index date (first observed vaccine dose) was required. Adherence was defined as receipt of the 2nd dose within 2-6 months, per label recommendation. Completion (receipt of all doses) was assessed at 6, 12, 18, and 24 months. RESULTS: Among 726,352 adults included, the adherence rate was 71.8%. Among 208,311 adults with 24-month follow-up, the completion rate was 72.3% after 6 months and 86.2% after 24 months. Logistic regression showed low adherence/completion was associated with younger age, Black or Hispanic race/ethnicity, lower income, lower educational attainment, and possessing commercial rather than Medicare healthcare insurance. Recipients identified using pharmacy claims had much higher adherence (74.0%) than those identified using medical claims (48.0%). CONCLUSIONS: Adherence and completion rates for RZV are suboptimal, especially for adults aged 50-64, racial/ethnic minorities, individuals with lower socio-economic status and those without Medicare insurance. More research and public health efforts are needed to understand and address potential barriers to RZV uptake, adherence and completion.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. LaMori J, Feng X, Pericone CD, et al. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021. Vaccine. 2022. PMID: 35292160. doi:10.1016/j.vaccine.2022.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。